Literature DB >> 18276722

Pathogenesis of cBFL in common with IPF? Correlation of IP-10/TARC ratio with histological patterns.

M Kishi1, Y Miyazaki, T Jinta, H Furusawa, Y Ohtani, N Inase, Y Yoshizawa.   

Abstract

BACKGROUND: A Th1 predominant immune response has been shown in acute hypersensitivity pneumonitis. Predominance of Th2 appears to favour the development of pulmonary fibrosis through the profibrotic process and has been described as crucial in the progression of idiopathic pulmonary fibrosis. Chronic bird fancier's lung (cBFL) can present with a histological pattern of usual interstitial pneumonia (UIP)-like lesions. Little is known about the Th1/Th2 balance in the pathogenesis of cBFL.
METHODS: To evaluate the relevance of Th1-type chemokines (interferon-inducible protein, IP-10) and Th2-type chemokines (thymus- and activation-regulated chemokine, TARC) and their receptors (CXCR3 and CCR4) to the histological patterns of cBFL, 40 patients with cBFL who underwent surgical lung biopsies, 12 with acute BFL (aBFL) and 10 healthy volunteers were analysed. IP-10 and TARC levels in serum and bronchoalveolar lavage (BAL) fluid were measured by ELISA. Immunohistochemistry for CXCR3 and CCR4 was performed on surgical lung specimens.
RESULTS: The ratio of TARC to IP-10 in the serum of patients with UIP-like lesions was significantly higher than in patients with cNSIP/OP-like lesions, aBFL and healthy volunteers. The ratio of CCR4 to CXCR3 in patients with UIP-like lesions was significantly higher than in those with cNSIP/OP-like lesions and fNSIP-like lesions. The ratio of CCR4-positive to CXCR3-positive cells correlated with the ratio of TARC to IP-10 in serum.
CONCLUSIONS: A Th2 predominant immune response may play an important role in the development of UIP-like lesions, as already observed in idiopathic pulmonary fibrosis. A Th1 predominance may play a role in the development of cNSIP/OP-like lesions in cBFL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276722     DOI: 10.1136/thx.2007.086074

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

1.  Identification of apolipoprotein A-I in BALF as a biomarker of sarcoidosis.

Authors:  Yoshihisa Nukui; Yasunari Miyazaki; Kozo Suhara; Tsukasa Okamoto; Haruhiko Furusawa; Naohiko Inase
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  Protein antigen of bird-related hypersensitivity pneumonitis in pigeon serum and dropping.

Authors:  Tsuyoshi Shirai; Haruhiko Furusawa; Asuka Furukawa; Yuki Ishige; Keisuke Uchida; Yasunari Miyazaki; Yoshinobu Eishi; Naohiko Inase
Journal:  Respir Res       Date:  2017-04-20

3.  Serum CXCL9 as a potential marker of Type 1 inflammation in the context of eosinophilic asthma.

Authors:  Takehiro Hasegawa; Takahiro Okazawa; Hitoshi Uga; Hirokazu Kurata; Akio Mori
Journal:  Allergy       Date:  2019-06-17       Impact factor: 13.146

4.  The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease.

Authors:  Peiyan Zheng; Xiaomao Zheng; Hasegawa Takehiro; Zhangkai Jason Cheng; Jingxian Wang; Mingshan Xue; Quanming Lin; Zhifeng Huang; Huimin Huang; Chenxi Liao; Baoqing Sun
Journal:  J Transl Int Med       Date:  2021-09-28

5.  Higher serum CCL17 may be a promising predictor of acute exacerbations in chronic hypersensitivity pneumonitis.

Authors:  Yasunari Miyazaki; Koji Unoura; Tomoya Tateishi; Takumi Akashi; Tamiko Takemura; Makoto Tomita; Naohiko Inase; Yasuyuki Yoshizawa
Journal:  Respir Res       Date:  2013-05-25

6.  Lung Infection by Human Bocavirus Induces the Release of Profibrotic Mediator Cytokines In Vivo and In Vitro.

Authors:  Soumaya Khalfaoui; Vivien Eichhorn; Christian Karagiannidis; Inga Bayh; Michael Brockmann; Monika Pieper; Wolfram Windisch; Oliver Schildgen; Verena Schildgen
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

7.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Christopher J Ryerson; Jeffrey L Myers; Michael Kreuter; Martina Vasakova; Elena Bargagli; Jonathan H Chung; Bridget F Collins; Elisabeth Bendstrup; Hassan A Chami; Abigail T Chua; Tamera J Corte; Jean-Charles Dalphin; Sonye K Danoff; Javier Diaz-Mendoza; Abhijit Duggal; Ryoko Egashira; Thomas Ewing; Mridu Gulati; Yoshikazu Inoue; Alex R Jenkins; Kerri A Johannson; Takeshi Johkoh; Maximiliano Tamae-Kakazu; Masanori Kitaichi; Shandra L Knight; Dirk Koschel; David J Lederer; Yolanda Mageto; Lisa A Maier; Carlos Matiz; Ferran Morell; Andrew G Nicholson; Setu Patolia; Carlos A Pereira; Elisabetta A Renzoni; Margaret L Salisbury; Moises Selman; Simon L F Walsh; Wim A Wuyts; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 30.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.